- Home
- MLTX
as 11-17-2025 3:44pm EST
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
| Founded: | 2021 | Country: | Switzerland |
| Employees: | N/A | City: | ZUG |
| Market Cap: | 904.7M | IPO Year: | N/A |
| Target Price: | $36.78 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.95 - $62.75 | Next Earning Date: | 11-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of MoonLake Immunotherapeutics (MLTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bodenstedt Matthias | MLTX | Chief Financial Officer | Oct 8 '25 | Buy | $9.09 | 10,870 | $98,808.30 | 627,536 | |
| Chen Bihua | MLTX | Other | Sep 30 '25 | Sell | $6.96 | 5,827 | $40,555.92 | 1,994,173 | |
| Chen Bihua | MLTX | Other | Sep 29 '25 | Sell | $7.99 | 6,494,151 | $46,827,628.18 | 1,994,173 |
Latest MoonLake Immunotherapeutics News
MLTX Breaking Stock News: Dive into MLTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 days ago
MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
GlobeNewswire
13 days ago
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
MT Newswires
15 days ago
HC wainwright Upgrades MoonLake Immunotherapeutics to Buy From Neutral
Simply Wall St.
a month ago
Chief Financial Officer of MoonLake Immunotherapeutics Matthias Bodenstedt Buys 1.8% More Shares
Simply Wall St.
a month ago
Can Legal Pressures Reshape Confidence in MoonLake Immunotherapeutics’ (MLTX) R&D Pipeline?
Simply Wall St.
a month ago
MoonLake Immunotherapeutics (MLTX): Assessing Valuation Following Phase 3 Trial Miss and Legal Scrutiny
MT Newswires
2 months ago
HC Wainwright Downgrades MoonLake Immunotherapeutics to Neutral From Buy
MT Newswires
2 months ago
Goldman Sachs Downgrades MoonLake Immunotherapeutics to Neutral From Buy, Cuts Price Target to $7 From $82
Compare MLTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MLTX MoonLake Immunotherapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.